A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 5,178 shares of DNLI stock, worth $127,844. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,178
Previous 4,258 21.61%
Holding current value
$127,844
Previous $98,000 53.06%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$20.96 - $31.05 $19,283 - $28,566
920 Added 21.61%
5,178 $150,000
Q2 2024

Jul 30, 2024

SELL
$14.96 - $23.22 $1 Million - $1.55 Million
-66,884 Reduced 94.01%
4,258 $98,000
Q1 2024

May 01, 2024

SELL
$15.83 - $23.35 $38,672 - $57,044
-2,443 Reduced 3.32%
71,142 $1.46 Million
Q4 2023

Jan 24, 2024

BUY
$16.2 - $23.18 $63,358 - $90,656
3,911 Added 5.61%
73,585 $1.58 Million
Q3 2023

Oct 26, 2023

SELL
$20.63 - $30.17 $82 - $120
-4 Reduced 0.01%
69,674 $1.44 Million
Q2 2023

Aug 10, 2023

BUY
$23.37 - $32.96 $63,099 - $88,992
2,700 Added 4.03%
69,678 $2.06 Million
Q1 2023

May 04, 2023

BUY
$21.91 - $32.67 $271,048 - $404,160
12,371 Added 22.65%
66,978 $1.54 Million
Q4 2022

Feb 09, 2023

BUY
$26.28 - $33.92 $150,032 - $193,649
5,709 Added 11.68%
54,607 $1.52 Million
Q3 2022

Nov 10, 2022

BUY
$25.97 - $38.53 $354,854 - $526,473
13,664 Added 38.78%
48,898 $1.5 Million
Q2 2022

Jul 26, 2022

BUY
$20.88 - $35.19 $735,685 - $1.24 Million
35,234 New
35,234 $1.04 Million
Q4 2021

Feb 08, 2022

SELL
$42.59 - $55.02 $298,854 - $386,075
-7,017 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$48.48 - $78.23 $56,285 - $90,825
1,161 Added 19.83%
7,017 $354,000
Q2 2021

Aug 11, 2021

BUY
$50.3 - $78.44 $294,556 - $459,344
5,856 New
5,856 $460,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.31B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.